Kamada-AAT intravenous Alpha-1 antitrypsin: Phase II/III data

Data from a double-blind, partial cross-over Phase II/III trial in 48 patients showed that weekly IV Kamada-AAT met the primary endpoint of non-inferiority in achieving antigenic and functional AAT le...